Table 3.

Odds ratio of CAC≥75^th percentile per SD increment of lipid measure or genetic risk score in the Framingham Heart Study Third Generation Cohort (n=1954)

Model	OR (95% CI)	P-value
LDL-C cholesterol
Age + sex	1.19 (1.06–1.34)	0.004
Age + sex + lipid treatment	1.23 (1.09–1.38)	0.0007
Age + sex + lipid treatment + LDL-C genetic risk score	1.22 (1.08–1.38)	0.001
LDL-C genetic risk score
Age + sex	1.06 (0.94–1.19)	0.33
Age + sex + lipid treatment	1.04 (0.92–1.17)	0.52
Age + sex + LDL-C + lipid treatment	1.02 (0.91–1.16)	0.72
HDL cholesterol
Age + sex	0.80 (0.71–0.90)	0.0003
Age + sex + lipid treatment	0.81 (0.72–0.92)	0.0007
Age + sex + lipid treatment + HDL-C genetic risk score	0.82 (0.72–0.93)	0.002
HDL-C genetic risk score
Age + sex	1.09 (0.97–1.22)	0.17
Age + sex + lipid treatment	1.08 (0.96–1.21)	0.19
Age + sex + HDL-C + lipid treatment	1.02 (0.91–1.16)	0.70
TG cholesterol
Age + sex	1.32 (1.17–1.48)	<0.0001
Age + sex + lipid treatment	1.30 (1.16–1.46)	<0.0001
Age + sex + lipid treatment + TG genetic risk score	1.32 (1.17–1.49)	<0.0001
TG genetic risk score
Age + sex	1.02 (0.90–1.14)	0.80
Age + sex + lipid treatment	1.01 (0.90–1.13)	0.92
Age + sex + TG + lipid treatment	0.94 (0.84–1.06)	0.35

Lipid levels and lipid treatment were assessed at Exam 1 in the Third Generation Cohort.